Share on StockTwits

Medicines (NASDAQ:MDCO) was downgraded by equities researchers at Jefferies Group from a “buy” rating to a “hold” rating in a research report issued on Thursday, reports. They currently have a $27.00 price target on the stock, down from their previous price target of $38.50. Jefferies Group’s target price indicates a potential downside of 18.43% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks downgraded shares of Medicines from a “neutral” rating to an “underperform” rating in a research note on Tuesday, February 4th. They now have a $32.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of Medicines from $41.00 to $50.00 in a research note on Thursday, December 5th. They now have an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $37.13.

Shares of Medicines (NASDAQ:MDCO) traded down 11.54% on Thursday, hitting $29.28. The stock had a trading volume of 5,218,346 shares. Medicines has a 1-year low of $28.63 and a 1-year high of $41.28. The stock has a 50-day moving average of $36.88 and a 200-day moving average of $34.71. The company has a market cap of $1.734 billion and a P/E ratio of 55.17.

The Medicines Company is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.